Cheeloo College of Medicine, Shandong University, Jinan, 250002, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, 230001, China.
J Exp Clin Cancer Res. 2022 Dec 7;41(1):337. doi: 10.1186/s13046-022-02547-3.
Altered glycolysis is the most fundamental metabolic change associated with the Warburg effect. Some glycolytic enzymes such as PKM2, the dominant pyruvate kinase in cancer cells, have been shown to engage in non-glycolytic functions that contribute to tumor metabolism. However, the precise mechanisms are not completely understood.
The role of MNX1-AS1 in hepatocellular carcinoma progression was assessed both in vitro and in vivo. Northern blotting, RNA pulldown, mass spectrometry, RNA-binding protein immunoprecipitation, ChIP, luciferase reporter assays, RNA FISH and immunofluorescence staining were used to explore the detail molecular mechanism of MNX1-AS1 in hepatocellular carcinoma (HCC).
Here we dissect how MNX1-AS1, a long non-coding RNA (lncRNA), reinforces the Warburg effect through facilitating the non-glycolytic actions of PKM2 in the cell nucleus. We found that MNX1-AS1 expression was frequently overexpressed in HCC-derived cell lines and tissues compared to their normal hepatic cell counterparts, a finding consistent with its status as pan-cancer expressed lncRNA. In the context of HCC, we show MNX1-AS1 acts as a scaffold to promote interactions between PKM2 and importin α5. In response to EGFR activation, the resulting ternary complex drives the translocation of PKM2 into the nucleus. In consequence, glycolytic pathway components including key mediators of the Warburg effect (LDHA, GLUT1 and PDK1) are upregulated though the coactivator function of PKM2. Manipulating MNX1-AS1 elicited robust effects on glycolysis associated with marked changes in HCC growth in vitro and in xenograft models, indicative of the significant contribution of MNX1-AS1 to tumorigenic phenotypes. Moreover, while MNX1-AS1 expression is driven by c-Myc, its actions associated with PKM2 were shown to be downstream and independent of c-Myc.
Given the status of MNX1-AS1 as a pan-cancer upregulated lncRNA, this implicitly highlights the potential of targeting MNX1-AS1 to selectively counter the Warburg effect in a range of tumor types.
糖酵解的改变是与沃伯格效应最相关的最基本的代谢变化。一些糖酵解酶,如 PKM2,癌细胞中主要的丙酮酸激酶,已经被证明具有非糖酵解功能,有助于肿瘤代谢。然而,确切的机制尚不完全清楚。
在体外和体内评估 MNX1-AS1 在肝细胞癌进展中的作用。采用Northern 印迹、RNA 下拉、质谱、RNA 结合蛋白免疫沉淀、ChIP、荧光素酶报告基因检测、RNA FISH 和免疫荧光染色等方法探讨 MNX1-AS1 在肝细胞癌(HCC)中的详细分子机制。
在这里,我们剖析了长链非编码 RNA(lncRNA)MNX1-AS1 如何通过促进 PKM2 在细胞核中的非糖酵解作用来加强沃伯格效应。我们发现,与正常肝细胞相比,MNX1-AS1 在肝癌衍生细胞系和组织中的表达经常过表达,这与它作为泛癌表达的 lncRNA 的地位一致。在 HCC 的背景下,我们表明 MNX1-AS1 作为支架促进 PKM2 与 Importinα5 之间的相互作用。响应 EGFR 激活,由此产生的三元复合物驱动 PKM2 进入细胞核。结果,糖酵解途径的成分,包括沃伯格效应的关键介质(LDHA、GLUT1 和 PDK1),通过 PKM2 的共激活功能上调。操纵 MNX1-AS1 在体外和异种移植模型中对糖酵解产生了显著影响,与 HCC 生长的明显变化相关,表明 MNX1-AS1 对肿瘤表型有显著贡献。此外,虽然 MNX1-AS1 的表达受 c-Myc 驱动,但与 PKM2 相关的作用被证明是下游的,并且独立于 c-Myc。
鉴于 MNX1-AS1 作为泛癌上调 lncRNA 的地位,这含蓄地强调了靶向 MNX1-AS1 以选择性地对抗多种肿瘤类型的沃伯格效应的潜力。